- Home
- WOK vs APLM Comparison
WOK vs APLM Comparison
Compare WOK & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOK
- APLM
- Stock Information
- Founded
- WOK 2002
- APLM 2016
- Country
- WOK China
- APLM United States
- Employees
- WOK N/A
- APLM N/A
- Industry
- WOK
- APLM Blank Checks
- Sector
- WOK
- APLM Finance
- Exchange
- WOK NYSE
- APLM Nasdaq
- Market Cap
- WOK 5.8M
- APLM 6.9M
- IPO Year
- WOK 2024
- APLM N/A
- Fundamental
- Price
- WOK $0.52
- APLM $4.89
- Analyst Decision
- WOK
- APLM
- Analyst Count
- WOK 0
- APLM 0
- Target Price
- WOK N/A
- APLM N/A
- AVG Volume (30 Days)
- WOK 159.0K
- APLM 6.9K
- Earning Date
- WOK 02-03-2025
- APLM 04-03-2025
- Dividend Yield
- WOK N/A
- APLM N/A
- EPS Growth
- WOK N/A
- APLM N/A
- EPS
- WOK N/A
- APLM N/A
- Revenue
- WOK $11,506,440.00
- APLM $198,000.00
- Revenue This Year
- WOK N/A
- APLM $415.15
- Revenue Next Year
- WOK N/A
- APLM N/A
- P/E Ratio
- WOK N/A
- APLM N/A
- Revenue Growth
- WOK N/A
- APLM N/A
- 52 Week Low
- WOK $0.36
- APLM $4.71
- 52 Week High
- WOK $8.45
- APLM $42.00
- Technical
- Relative Strength Index (RSI)
- WOK N/A
- APLM 35.08
- Support Level
- WOK N/A
- APLM $4.63
- Resistance Level
- WOK N/A
- APLM $5.45
- Average True Range (ATR)
- WOK 0.00
- APLM 0.54
- MACD
- WOK 0.00
- APLM -0.10
- Stochastic Oscillator
- WOK 0.00
- APLM 16.03
About WOK WORK MEDICAL TECHNOLOGY GROUP LTD
WORK Medical Technology Group Ltd is engaged in manufacturing and selling medical consumables through its wholly owned subsidiaries in the People's Republic of China. The Company's main products include medical face masks, tourniquets, airways, breathing circuits, intubation accessories, anesthesia kits, oxygen masks, suction sets, laryngoscope blades, KN95 masks, and other disposable medical devices, as well as medical equipment.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.